Shijiazhuang Yiling Pharmaceutical (002603.SZ): Withdrawal of the application for clinical trials of "G201-Na Capsules" medication.
Lingyun Pharmaceuticals (002603.SZ) announced that the company will follow the relevant drug approval policies and combine them with the progress of its research projects...
Shijiazhuang Yiling Pharmaceutical (002603.SZ) announced that, based on the relevant policies of drug approval and the progress of research projects, the company has decided, after careful consideration, to apply to the National Medical Products Administration (hereinafter referred to as "NMPA") to withdraw the clinical trial application for the drug "G201-Na Capsules" for the indication of "assisted reproduction". Recently, the company received the "Notice of Termination of Drug Registration Application" issued by the NMPA.
Related Articles
Shenzhen Hello Tech Energy(301327.SZ): Strong performance hits record high, revenue and net profit both break through.
Johnson & Johnson's financial condition is stable, and Standard and Poor's has removed the downgrade warning.
HK Bull/Bear Outstanding Qty Ratio(52:48) | April 26th
Shenzhen Hello Tech Energy(301327.SZ): Strong performance hits record high, revenue and net profit both break through.
Johnson & Johnson's financial condition is stable, and Standard and Poor's has removed the downgrade warning.
HK Bull/Bear Outstanding Qty Ratio(52:48) | April 26th
RECOMMEND
Pan Gongsheng: Will implement a moderately loose monetary policy to promote high-quality development of the Chinese economy.
25/04/2025
Canadian Prime Minister Trudeau: No rush to reach agreement with Trump, US side eventually needs to face reality.
25/04/2025
Alphabet (GOOG.US, GOOGL.US) first quarter revenue and profits exceed expectations, driven by AI and cloud computing performance growth.
25/04/2025
